Impax Asset Management Group plc
Notice of results
London, 12 November 2015 - Impax Asset Management Group plc ("Impax" or the "Company"), expects to announce its results for the year ended 30 September 2015 on Thursday 3 December 2015.
There will be a conference call for analysts on the day of the results at 9.00am.
A copy of the presentation will be made available on the Company's website from 7.30am on 3 December 2015.
Anne Gilding Tel: +44 (0) 20 7434 1122 (switchboard)
Head of Brand Communications Tel: +44 (0) 20 7432 2602 (direct)
Impax Asset Management Group plc Tel: +44 (0) 7881 249612 (mobile)
Guy Wiehahn Tel: +44 (0) 20 7418 8893
Peel Hunt LLP
Notes to Editors - About Impax Asset Management
Impax Asset Management is a leading investment firm, managing approximately £3bn* primarily for institutional clients through both listed and private equity strategies.
Impax's investments are based on a strong conviction that population dynamics, resource scarcity, inadequate infrastructure and environmental constraints will profoundly shape global markets, creating investment risks and opportunities. The Company expects that these trends, reflecting the transition towards a more sustainable global economy, will drive earnings growth for well-positioned companies. Impax's proprietary investment framework identifies and calibrates the rising risks and expanding opportunities from this transition, and guides the search for investments that will deliver long term outperformance.
Impax is a holder of a Queen's Award for Enterprise: Sustainable Development and numerous other industry awards.
*As at 31 October 2015
Issued in the UK by Impax Asset Management Group plc, whose shares are quoted on AIM. Impax Asset Management Group plc is registered in England & Wales, number 03262305.
AUM relates to Impax Asset Management Limited and Impax Asset Management (AIFM) Limited. Both companies are authorised and regulated by the Financial Conduct Authority and are wholly owned subsidiaries of Impax Asset Management Group plc.
Please note that the information provided and links from it should not be relied upon for investment purposes. For further information please visit www.impaxam.com
This information is provided by RNS